Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy

BACKGROUND: We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. In that study, mean body weight was decreased by 3.5 kg (4.3% of the baseline value) after ipraglifloz...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Yoshio, Fukuda, Hisashi, Kawanabe, Shin, Nakagawa, Tomoko, Ohta, Akio, Tanaka, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436566/
https://www.ncbi.nlm.nih.gov/pubmed/30937121
http://dx.doi.org/10.14740/jocmr3785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436566/
https://www.ncbi.nlm.nih.gov/pubmed/30937121
http://dx.doi.org/10.14740/jocmr3785

Ejemplares similares